Consolidated Statements of Operations (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Statements of Operations      
Diagnostic services revenue, net $ 151,569 $ 119,556 $ 46,457
Cost of diagnostic services revenue 83,475 87,302 47,283
Gross margin 68,094 32,254 (826)
Operating expenses:      
Selling and marketing 30,826 37,588 33,795
Research and development 25,005 38,735 40,242
General and administrative 46,910 52,545 39,782
Restructuring costs 1,907 5,753 0
Total operating expenses 104,648 134,621 113,819
Gain on pooled patents agreement 22,850 0 0
Operating loss (13,704) (102,367) (114,645)
Interest expense 8,184 8,589 3,417
Interest income 55 146 99
Other expense, net (207) (110) (12)
Loss from continuing operations before income taxes (22,040) (110,920) (117,975)
Income tax benefit 7,676 1,353 684
Loss from continuing operations (14,364) (109,567) (117,291)
Earnings from discontinued operations, net of tax 15,376 2,161 262
Net earnings (loss) 1,012 [1] (107,406) [2] (117,029)
Net earnings (loss) per common share, basic and diluted      
Continuing operations (in USD per share) $ (0.12) $ (0.95) $ (1.03)
Discontinued operations (in USD per share) $ 0.13 $ 0.02 $ 0.00
Net loss per common share, basic and diluted (in USD per share) $ 0.01 $ (0.93) $ (1.03)
Weighted average number of shares outstanding, basic and diluted (in shares) 116,729 115,378 113,646
Weighted average number of shares outstanding, basic (in shares) 116,729    
Statements of Comprehensive Income (Loss)      
Net earnings (loss) 1,012 [1] (107,406) [2] (117,029)
Other comprehensive income (loss):      
Unrealized gain (loss) on available-for-sale securities, net of taxes (26) 51 (24)
Foreign currency translation adjustment 63 201 261
Write-off of permanent investment in subsidiary upon dissolution (625)   1,011
Total other comprehensive income (loss) (588) 252 1,248
Comprehensive income (loss) $ 424 $ (107,154) $ (115,781)
[1] Net earnings during the fourth quarter of 2014 includes a $22.9 million gain from the Pooled Patents Agreement. That gain was offset by a $1.2 million tax expense due to a reduction in a tax benefit estimated in the prior quarter. The first and second quarter of 2014 include restructuring costs of $0.9 million and $1.0 million, respectively.
[2] Net loss during the third quarter of 2013 includes $5.7 million in restructuring costs and impairment charges.